Clinical trials: Metastatic Colorectal Neoplasms
Colorectal Cancer Metastatic
Improving SUrgery of Liver Metastases: a Trial of the Arterial Chemotherapy Network
National trial, multicenter, randomized, phase II comparing treatment intensification with hepatic arterial infusion chemotherapy plus systemic chemotherapy (CT) to systemic chemotherapy alone in patients with liver-only…
- Trial name
- SULTAN (NCT03164655)
- Testing
- Oxaliplatin, Cetuximab, Bevacizumab, Panitumumab, Irinotecan, Leucovorin, 5-Fluorouracil
- Where
- 4 sites in France
- Volunteers
- 20 people
- Sponsor
- UNICANCER
Colorectal Cancer, Metastatic Cancer
Cryosurgery in Treating Patients With Unresectable Liver Metastases From Colorectal Cancer
RATIONALE: Cryosurgery for liver metastases may have fewer side effects and improve recovery. PURPOSE: Phase II trial to study the effectiveness of cryosurgery for patients with unresectable liver metastases from colorectal…
- Trial name
- NCT00002997
- Testing
- cryosurgery
- Where
- 3 sites in United States
- Sponsor
- Eastern Cooperative Oncology Group
Colorectal Cancer Metastatic
An Explorative Study of HRS-2189 Combined With Adebrelimab and BP102 for Metastatic Colorectal Cancer
To evaluate the safety and efficacy of HRS-2189 combined with Adebrelimab and BP102 in the treatment of metastatic colorectal cancer
- Trial name
- NCT07061210
- Testing
- HRS-2189, Adebrelimab, BP102
- Volunteers
- 20 people
- Sponsor
- Fudan University
Colorectal Cancer, Significant Bowel Pathology
Optimising Colorectal Cancer Patient Pathways
Bowel cancer (colorectal cancer) is the 4th most common cancer in Scotland. Approximately 4,000 cases are diagnosed annually. Cancer-related deaths in Scotland are higher than other UK nations.
- Trial name
- NCT07430540
- Testing
- Additional FIT testing
- Where
- United Kingdom
- Volunteers
- 1,000 people
- Sponsor
- University of Edinburgh
Rectal Adenocarcinoma, Recurrent Rectal Carcinoma
TAS-102 and Radiation Therapy in Treating Patients With Rectal Cancer That Is Locally Recurrent, Metastatic, or Cannot Be Removed by Surgery
This phase I trial studies the side effects and best dose of trifluridine/tipiracil hydrochloride combination agent TAS-102 (TAS-102) when given together with radiation therapy in treating patients with rectal cancer that has…
- Conditions
- Rectal Adenocarcinoma, Recurrent Rectal Carcinoma, Stage IV Rectal Cancer AJCC v7, Stage IVA Rectal Cancer AJCC v7
- Trial name
- NCT03297710
- Testing
- Quality-of-Life Assessment, Radiation Therapy, Trifluridine/Tipiracil Hydrochloride Combination Agent TAS-102
- Where
- 2 sites in United States
- Volunteers
- 7 people
- Sponsor
- Mayo Clinic
Colorectal Cancer, Metastasis
Pulsatile High-dose Sunitinib Versus TAS-102 in Patients With Metastatic Colorectal Carcinoma (mCRC)
The purpose of this study is to compare progression free survival rates of metastasized colorectal cancer patients refractory or intolerant to systemic therapy with fluoropyrimidine, irinotecan, oxaliplatin, anti-VEGF therapy and…
- Trial name
- SUNRISE-CRC (NCT03909724)
- Testing
- Sunitinib Malate, TAS 102
- Where
- Netherlands
- Volunteers
- 60 people
- Sponsor
- Amsterdam UMC, location VUmc
Metastatic Colorectal Cancer
PROSPECT-C: A Study of Biomarkers of Response or Resistance to Anti-EGFR Therapies in Metastatic Colorectal Cancer
PROSPECT-C is a phase II study investigating the molecular markers of response or resistance to anti-epidermal growth factor receptor (EGFR) antibodies.
- Trial name
- PROSPECT-C (NCT02994888)
- Testing
- Cetuximab
- Where
- United Kingdom
- Volunteers
- 47 people
- Sponsor
- Royal Marsden NHS Foundation Trust
Metastatic Colorectal Cancer
An Exploratory Pharmacogenomic Study of Monotherapy Erbitux in Subjects With Metastic Colorectal Cancer
The purpose of this study is to predict response to Erbitux as a single agent in patients with metastatic colon cancer
- Trial name
- NCT00207155
- Testing
- Cetuximab
- Where
- 14 sites in United States, Canada and 1 more
- Volunteers
- 110 people
- Sponsor
- Eli Lilly and Company
Colorectal Cancer, Liver Metastasis
Compare Efficacy and Safety of Raltitrexed-based and 5fu-based Neoadjuvant Chemotherapy for Colorectal Liver Metastasis
This study is a multicenter ,randomization, open control study to evaluate the efficacy and safety of Raltitrexed-based chemotherapy and 5-fluorouracil-based chemotherapy in the peri-operative treatment of patients with Liver…
- Trial name
- NCT02453490
- Testing
- Raltitrexed-based chemotherapy, 5-fluorouracil-based chemotherapy
- Where
- 9 sites in China
- Volunteers
- 360 people
- Sponsor
- Zhejiang University
Human Papillomavirus-16 Positive, Human Papillomavirus-18 Positive
DNA Plasmid-encoding Interleukin-12/HPV DNA Plasmids Therapeutic Vaccine INO-3112 and Durvalumab in Treating Patients With Recurrent or Metastatic Human Papillomavirus Associated Cancers
This phase II trial studies how well deoxyribonucleic acid (DNA) plasmid-encoding interleukin-12/human papillomavirus (HPV) DNA plasmids therapeutic vaccine INO-3112 and durvalumab work in treating patients with human…
- Conditions
- Human Papillomavirus-16 Positive, Human Papillomavirus-18 Positive, Metastatic Malignant Neoplasm, Recurrent Anal Canal Carcinoma
- Trial name
- NCT03439085
- Testing
- DNA Plasmid-encoding Interleukin-12/HPV DNA Plasmids Therapeutic Vaccine MEDI0457, Durvalumab
- Where
- United States
- Volunteers
- 41 people
- Sponsor
- M.D. Anderson Cancer Center
Colorectal Adenocarcinoma, Metastatic Cholangiocarcinoma
CD8+ T Cell Therapy and Pembrolizumab in Treating Patients With Metastatic Gastrointestinal Tumors
This phase I pilot trial studies the side effects of cluster of differentiation 8 (CD8)+ T cells in treating patients with gastrointestinal tumors that have spread to other places in the body.
- Conditions
- Colorectal Adenocarcinoma, Metastatic Cholangiocarcinoma, Metastatic Colorectal Carcinoma, Metastatic Digestive System Carcinoma
- Trial name
- NCT02757391
- Testing
- Adoptive Immunotherapy, Aldesleukin, Cyclophosphamide
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- M.D. Anderson Cancer Center
Breast Cancer, Colorectal Cancer
An Observational Pilot Study Evaluating the Feasibility of Conducting Genome-Wide Association Studies Utilizing Subject Provided Information in Subjects With Locally Recurrent or MBC, MCRC, MNSCLC, RGBM or MRCC Treated With Avastin (Bevacizumab) (InVite)
This pilot, non-interventional, observational, Web-based, prospective cohort study is designed to collect self-reported safety and effectiveness and genetic data from subjects with locally recurrent breast cancer (BC) or…
- Conditions
- Breast Cancer, Colorectal Cancer, Non-Small Cell Lung Cancer, Glioblastoma
- Trial name
- NCT01598597
- Where
- 50 sites in United States
- Volunteers
- 276 people
- Sponsor
- Genentech, Inc.
Metastatic Colorectal Cancer (mCRC), Colorectal Neoplasms
Efficacy And Safety Of Hydroxychloroquine Combined With Methotrexate, Capecitabine And Bevacizumab Vs. Regorafenib In Participants With Refractory Metastatic Colorectal Cancer With Mutations In RAS Genes
This study will evaluate efficacy and safety of hydroxychloroquine combined with methotrexate, capecitabine and bevacizumab versus regorafenib in participants with refractory metastatic colorectal cancer with mutations in KRAS or…
- Trial name
- x-МАР (NCT06949982)
- Testing
- experimental group x-MAP, Regorafenib (BAY 73-4506)
- Where
- Russia
- Volunteers
- 60 people
- Sponsor
- Sergey Orlov, MD
Refractory Metastatic Colorectal Cancer
Ivarmacitinib Combined With Camrelizumab and Fruquintinib for Patients With Metastatic Colorectal Cancer After Failure of Second-line or Later Treatment
For patients with metastatic colorectal cancer (mCRC) who have failed two or more lines of standard therapy, treatment options are extremely limited, and the prognosis remains poor, with objective response rates (ORRs) generally…
- Trial name
- NCT07896096
- Testing
- Ivarmacitinib Sulfate Tablets, Camrelizumab, Fruquintinib
- Where
- China
- Volunteers
- 33 people
- Sponsor
- Renmin Hospital of Wuhan University
Metastatic Colorectal Cancer
Study of Trastuzumab-emtansine in Patients With HER2-positive Metastatic Colorectal Cancer Progressing After Trastuzumab and Lapatinib.
This is a phase II, open label, multicenter study. Patients with advanced colon rectal cancer (CRC) harboring an amplified HER2 that have been previously treated and progressed with an aNti-HER2 treatment, will be treated with…
- Trial name
- RESCUE (NCT03418558)
- Testing
- Trastuzumab emtansine
- Where
- 3 sites in Italy
- Volunteers
- 13 people
- Sponsor
- Fondazione del Piemonte per l'Oncologia
Colorectal Cancer Metastatic
Study to Evaluate Real-world Pharmacoeconomics of Panitumumab in Metastatic Colorectal Cancer Patients
This is a phase IV multicenter trial to evaluate real-world health outcomes and economic impact of panitumumab versus standard-of-care (SOC) in the treatment of patients with chemotherapy-refractory metastatic colorectal cancer…
- Trial name
- NCT02139215
- Where
- 5 sites in Canada
- Volunteers
- 72 people
- Sponsor
- PeriPharm
Metastatic Colorectal Adenocarcinoma
Trifluridine/Tipiracil Plus Bevacizumab Versus Trifluridine/Tipiracil Monotherapy in Refractory Metastatic Colorectal Cancer
This study is a retrospective study to compare the efficacy and safety between trifluridine/tipiracil (TAS-102) plus bevacizumab (BEV) with TAS-102 monotherapy in refractory metastatic colorectal cancer (mCRC) from November 2020…
- Trial name
- NCT05869097
- Testing
- Trifluridine/Tipiracil, Bevacizumab
- Where
- China
- Volunteers
- 90 people
- Sponsor
- Hunan Cancer Hospital
Metastatic Colorectal Cancer
FLOX + Cetuximab (Erbitux®) for Patients With Metastatic Colorectal Cancer and Wild Type K-RAS Tumor
The Nordic FLOX-regime consists of a combination of bolus 5-FU, leukovorin and oxaliplatin (Eloxatin®). Cetuximab (Erbitux®) is an antibody against the epidermal growth factor receptor (EGFR).
- Trial name
- NCT00660582
- Testing
- Cetuximab (Erbitux), Oxaliplatin (Eloxatin) + Fluorouracil + folinic acid
- Where
- 6 sites in Denmark, Norway and 1 more
- Volunteers
- 152 people
- Sponsor
- Per Pfeiffer
Metastatic Colorectal Cancer (CRC), Liposomal Irinotecan
A Clinical Study of Liposomal Irinotecan for Second-Line Therapy in Metastatic Colorectal Cancer
Phase II - Treatment Regimen Exploration Stage: 1. Evaluate the safety and efficacy of the following three treatment regimens: Liposomal irinotecan + 5-FU/LV + bevacizumab + Enlonstobart (Group A) Liposomal irinotecan + 5-FU/LV +…
- Conditions
- Metastatic Colorectal Cancer (CRC), Liposomal Irinotecan, Second-Line
- Trial name
- NCT07585279
- Testing
- Liposomal irinotecan + 5-FU/LV + bevacizumab + Enlonstobart, Irinotecan liposome + 5-FU/LV + Bevacizumab, Irinotecan + 5-FU/LV + Bevacizumab
- Where
- China
- Volunteers
- 408 people
- Sponsor
- Hebei Medical University Fourth Hospital
Benign Neoplasm of Intestinal Tract, Primary Malignant Neoplasm of Intestinal Tract
Impact of Perioperative Intravenous Fluid Utilization on Postoperative Outcomes
Subjects undergoing surgery on the small or large bowel will be randomized to one of 2 groups, a normal fluid amount group and a reduced fluid amount group to evaluate the impact of this change on recovery after surgery.
- Conditions
- Benign Neoplasm of Intestinal Tract, Primary Malignant Neoplasm of Intestinal Tract, Secondary Malignant Neoplasm of Intestinal Tract
- Trial name
- NCT01563991
- Testing
- Normal fluid volume, Reduced fluid volume
- Where
- United States
- Volunteers
- 186 people
- Sponsor
- The Cleveland Clinic
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.